Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | IL1RN | P18510 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13427297 | 0.85 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL30291613 | 0.83 | MMP1 (0.53) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL20466157 | 0.82 | POLB (0.54) | MAPTTDP1POLBIL1RNERAP2 | |
| SCHEMBL1437012 | 0.82 | MMP1 (0.57) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL27041650 | 0.82 | CTSK (0.60) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL1486271 | 0.82 | IL1RN (0.61) | POLBIL1RNERAP2ERAP1BIRC2 | |
| SCHEMBL27041646 | 0.82 | CTSK (0.60) | MMP1MMP3MMP9MAPTTDP1 | |
| SCHEMBL13101947 | 0.82 | GPR88 (0.47) | CTSSCTSKMETAP2 | |
| Hydrochloric Acid SCHEMBL5966853 | 0.81 | MMP1 (0.56) | MMP1MMP3MMP9MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL27530934 | 0.81 | MMP1 (0.56) | MMP1MMP3MMP9MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | MMP1 524/4885MMP3 438/4885MMP9 613/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | MMP1 524/4885MMP3 438/4885MMP9 613/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | MMP1 524/4885MMP3 438/4885MMP9 613/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | MMP1 276/4885MMP3 190/4885MMP9 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.